DE CARNE KOEN: what changed
What changed
DE CARNE KOEN
NACE 47.730, Retail sale of pharmaceutical products
filed annual accounts (NBB)
Net result for the year
-€19,596
2024 · €4,458-€24,055
Equity
€154,047
2024 · €173,644-€19,596
Cash
-
not filed
Balance sheet total
€429,003
2024 · €440,770-€11,767
Largest movements
Assets
- Tangible fixed assets -€27,125
down €27,125 (-8.7%), from €310,940 to €283,815
- Receivables within one year +€20,236
up €20,236 (+48.5%), from €41,741 to €61,978
of which Trade receivables: +€17,774
Equity and liabilities
- Trade debts +€30,104
up €30,104 (+47.4%), from €63,499 to €93,602
- Profit (loss) carried forward -€19,596
down €19,596 (-10.5%), from -€186,717 to -€206,313
- Current portion of long-term debt -€18,726
down €18,726 (-79.9%), from €23,448 to €4,722
- Short-term financial debts +€5,480
up €5,480 (+11.1%), from €49,290 to €54,770
- Other debts -€5,413
down €5,413 (-5.3%), from €101,364 to €95,951
Income statement
- Gross operating margin -€24,411
down €24,411 (-52.8%), from €46,237 to €21,826
- Other operating charges -€607
down €607 (-18.1%), from €3,362 to €2,755
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
€4,458
Gross operating margin
-€24,411
Other operating charges
+€607
Financial income
-€41
Financial charges
-€232
Taxes
+€21
Result 2025
-€19,596
raises the resultlowers the result
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts. So the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €440,770 | €429,003 | -€11,767 | -2.7% |
| Fixed assets | 21/28 | €310,940 | €283,815 | -€27,125 | -8.7% |
| Tangible fixed assets | 22/27 | €310,940 | €283,815 | -€27,125 | -8.7% |
| Land and buildings | 22 | €310,940 | €283,815 | -€27,125 | -8.7% |
| Current assets | 29/58 | €129,830 | €145,188 | +€15,359 | +11.8% |
| Stocks and contracts in progress | 3 | €78,469 | €74,986 | -€3,483 | -4.4% |
| Stocks | 30/36 | €78,469 | €74,986 | -€3,483 | -4.4% |
| Amounts receivable within one year | 40/41 | €41,741 | €61,978 | +€20,236 | +48.5% |
| Trade receivables | 40 | €39,616 | €57,390 | +€17,774 | +44.9% |
| Other amounts receivable | 41 | €2,126 | €4,588 | +€2,462 | +116% |
| Current investments | 50/53 | €7,000 | €7,000 | = | 0.0% |
| Deferred charges and accrued income | 490/1 | €2,619 | €1,224 | -€1,395 | -53.3% |
| Total equity and liabilities | 10/49 | €440,770 | €429,003 | -€11,767 | -2.7% |
| Equity | 10/15 | €173,644 | €154,047 | -€19,596 | -11.3% |
| Contributions | 10/11 | €24,789 | €24,789 | = | 0.0% |
| Revaluation surpluses | 12 | €321,092 | €321,092 | = | 0.0% |
| Reserves | 13 | €14,479 | €14,479 | = | 0.0% |
| Distributable reserves | 133 | €14,479 | €14,479 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€186,717 | -€206,313 | -€19,596 | -10.5% |
| Amounts payable | 17/49 | €267,126 | €274,956 | +€7,830 | +2.9% |
| Amounts payable after more than one year | 17 | €8,808 | €4,086 | -€4,722 | -53.6% |
| Financial debts | 170/4 | €8,808 | €4,086 | -€4,722 | -53.6% |
| Amounts payable within one year | 42/48 | €237,735 | €249,610 | +€11,874 | +5.0% |
| Current portion of amounts payable after more than one year | 42 | €23,448 | €4,722 | -€18,726 | -79.9% |
| Financial debts | 43 | €49,290 | €54,770 | +€5,480 | +11.1% |
| Credit institutions | 430/8 | €49,290 | €54,770 | +€5,480 | +11.1% |
| Trade debts | 44 | €63,499 | €93,602 | +€30,104 | +47.4% |
| Suppliers | 440/4 | €63,499 | €93,602 | +€30,104 | +47.4% |
| Taxes, remuneration and social security | 45 | €135 | €565 | +€430 | +319% |
| Taxes | 450/3 | €135 | €565 | +€430 | +319% |
| Other amounts payable | 47/48 | €101,364 | €95,951 | -€5,413 | -5.3% |
| Accrued charges and deferred income | 492/3 | €20,583 | €21,260 | +€677 | +3.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €27,125 | €27,125 | = | 0.0% |
| Other operating charges | 640/8 | €3,362 | €2,755 | -€607 | -18.1% |
| Gross operating margin | 9900 | €46,237 | €21,826 | -€24,411 | -52.8% |
| Operating profit (loss) | 9901 | €15,749 | -€8,054 | -€23,804 | |
| Financial income | 75/76B | €72 | €32 | -€41 | -56.2% |
| Recurring financial income | 75 | €72 | €32 | -€41 | -56.2% |
| Financial charges | 65/66B | €11,127 | €11,358 | +€232 | +2.1% |
| Recurring financial charges | 65 | €11,127 | €11,358 | +€232 | +2.1% |
| Profit (loss) for the period before taxes | 9903 | €4,695 | -€19,381 | -€24,076 | |
| Income taxes | 67/77 | €237 | €216 | -€21 | -9.0% |
| Profit (loss) for the period | 9904 | €4,458 | -€19,596 | -€24,055 | |
| Profit (loss) for the period to be appropriated | 9905 | €4,458 | -€19,596 | -€24,055 |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 3 November 2026 via checked.be.